Tumor Purity-Related Genes for Predicting the Prognosis and Drug Sensitivity of DLBCL Patients

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the predominant type of malignant B-cell lymphoma. Although various treatments have been developed, the limited efficacy calls for more and further exploration of its characteristics.Datasets from Gene Expression Omnibus (GEO) database were used for identifying the tumor purity of DLBCL. Survival analysis was employed for analyzing the prognosis of DLBCL patients. Immunohistochemistry was conducted to detect the important factor that influenced the prognosis. Drug sensitive prediction was performed to evaluate the value of the constructed model.VCAN, CD3G and C1QB were identified as three key genes that impacted the outcome of DLBCL patients both in GEO datasets and samples from our center. Among them, VCAN and CD3G+ T cells were correlated with favorable prognosis, and C1QB was correlated with worse prognosis. The ratio of CD68+ macrophages and CD8+ T cells was associated with better prognosis. In addition, CD3G+ T cells ratio was significantly correlated with CD68+ macrophages, CD4+ T cells and CD8+ T cells ratio, indicating it could play an important role in the anti-tumor immunity in DLBCL. The riskScore model constructed based on the RNASeq data of VCAN, C1QB and CD3G work well in predicting the prognosis and drug sensitivity.VCAN, CD3G and C1QB were three key genes that influenced the tumor purity of DLBCL, and could also exert certain impact on drug sensitivity and prognosis of DLBCL patients.